Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

1.

A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.

Rocha-Lima CM, de Queiroz Marques Junior E, Bayraktar S, Broome P, Weissman C, Nowacki M, Leslie M, Susnerwala S.

Cancer Chemother Pharmacol. 2014 Sep;74(3):479-86. doi: 10.1007/s00280-014-2520-y. Epub 2014 Jul 17.

PMID:
25030089
[PubMed - in process]
2.

Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system.

Hosein PJ, Echenique A, Loaiza-Bonilla A, Froud T, Barbery K, Rocha Lima CM, Yrizarry JM, Narayanan G.

J Vasc Interv Radiol. 2014 Aug;25(8):1233-1239.e2. doi: 10.1016/j.jvir.2014.04.007. Epub 2014 May 24.

PMID:
24861662
[PubMed - in process]
3.

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.

Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM.

Cancer Chemother Pharmacol. 2014 Apr;73(4):839-45. doi: 10.1007/s00280-014-2414-z. Epub 2014 Feb 23.

PMID:
24562589
[PubMed - indexed for MEDLINE]
4.

Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.

Palacio S, Loaiza-Bonilla A, Kittaneh M, Kyriakopoulos C, Ochoa RE, Escobar M, Arango B, Restrepo MH, Merchan JR, Rocha Lima CM, Hosein PJ.

Anticancer Res. 2014 Jan;34(1):301-6.

PMID:
24403478
[PubMed - indexed for MEDLINE]
5.

Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma.

Bayraktar S, Rocha-Lima CM.

World J Clin Oncol. 2013 May 10;4(2):29-42. doi: 10.5306/wjco.v4.i2.29.

PMID:
23696960
[PubMed]
Free PMC Article
6.

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.

Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M.

Ann Oncol. 2013 Jul;24(7):1792-801. doi: 10.1093/annonc/mdt066. Epub 2013 Feb 28.

PMID:
23448807
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.

Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ.

Cancer Chemother Pharmacol. 2013 Feb;71(2):523-30. doi: 10.1007/s00280-012-2045-1. Epub 2012 Dec 11.

PMID:
23228990
[PubMed - indexed for MEDLINE]
8.

Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma.

Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, Franceschi D, Rocha Lima CM, Yrizarry J.

J Vasc Interv Radiol. 2012 Dec;23(12):1613-21. doi: 10.1016/j.jvir.2012.09.012.

PMID:
23177107
[PubMed - indexed for MEDLINE]
9.

Emerging cell-cycle inhibitors for pancreatic cancer therapy.

Bayraktar S, Rocha Lima CM.

Expert Opin Emerg Drugs. 2012 Dec;17(4):571-82. doi: 10.1517/14728214.2012.739606. Epub 2012 Nov 5. Review.

PMID:
23126234
[PubMed - indexed for MEDLINE]
10.

A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer.

Rocha Lima CM, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, Papageorgio C, Auber ML, Kaleta R, McHenry MB, Trifan OC, Philip PA.

Gastrointest Cancer Res. 2012 Sep;5(5):155-60.

PMID:
23112883
[PubMed]
Free PMC Article
11.

Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Rocha Lima CM, Bayraktar S, Flores AM, MacIntyre J, Montero A, Baranda JC, Wallmark J, Portera C, Raja R, Stern H, Royer-Joo S, Amler LC.

Cancer Invest. 2012 Dec;30(10):727-31. doi: 10.3109/07357907.2012.732163. Epub 2012 Oct 12.

PMID:
23061802
[PubMed - indexed for MEDLINE]
12.

Oxaliplatin induced disseminated intravascular coagulation: A case report and review of literature.

Kurian S, Macintyre J, Mushtaq M, Rocha-Lima CM, Ahn Y.

World J Gastrointest Oncol. 2012 Jul 15;4(7):181-3. doi: 10.4251/wjgo.v4.i7.181.

PMID:
22844549
[PubMed]
Free PMC Article
13.

Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature.

Akunyili I, Garcia-Buitrago MT, Macintyre J, Levi J, Rocha Lima CM.

J Gastrointest Oncol. 2011 Jun;2(2):117-21. doi: 10.3978/j.issn.2078-6891.2011.016. No abstract available.

PMID:
22811840
[PubMed]
Free PMC Article
14.

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS.

Ann Oncol. 2012 Nov;23(11):2834-42. doi: 10.1093/annonc/mds142. Epub 2012 Jun 13.

PMID:
22700995
[PubMed - indexed for MEDLINE]
Free Article
15.

Successful treatment of anal gland adenocarcinoma with combined modality therapy.

Warsch S, Bayraktar UD, Wen BC, Zeitouni J, Marchetti F, Rocha-Lima CM, Montero AJ.

Gastrointest Cancer Res. 2012 Mar;5(2):64-6. No abstract available.

PMID:
22690260
[PubMed]
Free PMC Article
16.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM.

BMC Cancer. 2012 May 29;12:199. doi: 10.1186/1471-2407-12-199.

PMID:
22642850
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes.

Ochoa R, Sudhindra A, Garcia-Buitrago M, Romilly AP, Cortes J, Gomez H, Rocha Lima CM, Silva O.

Clin Breast Cancer. 2012 Aug;12(4):287-92. doi: 10.1016/j.clbc.2012.03.007. Epub 2012 Apr 20. Review. No abstract available.

PMID:
22520734
[PubMed - indexed for MEDLINE]
18.

A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.

Hosein PJ, de Lima Lopes G Jr, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM.

Am J Clin Oncol. 2013 Apr;36(2):151-6. doi: 10.1097/COC.0b013e3182436e8c.

PMID:
22307213
[PubMed - indexed for MEDLINE]
19.

A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors.

Rocha-Lima CM, Bayraktar S, Macintyre J, Raez L, Flores AM, Ferrell A, Rubin EH, Poplin EA, Tan AR, Lucarelli A, Zojwalla N.

Cancer. 2012 Sep 1;118(17):4262-70. doi: 10.1002/cncr.27428. Epub 2012 Jan 31.

PMID:
22294459
[PubMed - indexed for MEDLINE]
Free Article
20.

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.

Bayraktar UD, Bayraktar S, Hosein P, Chen E, Koniaris LG, Rocha-Lima CM, Montero AJ.

Med Oncol. 2012 Sep;29(3):1707-10. doi: 10.1007/s12032-011-0093-8. Epub 2011 Oct 28.

PMID:
22033912
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk